DRG 018

Medical DRG

Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies

Linked ICD-10-PCS Procedure Mappings

  • XHR0XGA

    Replacement of Head and Neck Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR1XGA

    Replacement of Chest Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR2XGA

    Replacement of Abdomen Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR3XGA

    Replacement of Back Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR4XGA

    Replacement of Right Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR5XGA

    Replacement of Left Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR6XGA

    Replacement of Right Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR7XGA

    Replacement of Left Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XW0331B

    Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW03368

    Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

    BillableSection X
  • XW03378

    Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

    BillableSection X
  • XW0338A

    Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW033A7

    Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033BA

    Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW033C7

    Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033FA

    Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW033FB

    Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW033G7

    Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033H7

    Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033J7

    Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033K7

    Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033L7

    Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033M7

    Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033N7

    Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033RB

    Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW0431B

    Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW04368

    Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

    BillableSection X
  • XW04378

    Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

    BillableSection X
  • XW0438A

    Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW043A7

    Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043BA

    Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW043C7

    Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043FA

    Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW043FB

    Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW043G7

    Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043H7

    Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043J7

    Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043K7

    Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043L7

    Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043M7

    Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043N7

    Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043RB

    Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X